Baltimore, MDNCT04601038Now EnrollingIRB Ready

Mild Cognitive Impairment Clinical Trial in Baltimore, MD

Access cutting-edge mild cognitive impairment treatment through this phase 2 clinical trial at a research site in Baltimore. Study-provided care at no cost to qualified participants.

Sponsored by Johns Hopkins University

Quick Self-Assessment

See if you qualify for this Baltimore location

Preparing your pre-screening questions…

Expert Care in Baltimore

Access mild cognitive impairment specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related mild cognitive impairment treatment provided free

Apply for This Baltimore Location

Check if you qualify for this mild cognitive impairment clinical trial in Baltimore, MD

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Baltimore

    Convenient for MD residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Baltimore site if eligible
  4. 4Begin participation

About This Mild Cognitive Impairment Study in Baltimore

CORT-X will examine if mitigation of stress-mediated pathogenesis of Alzheimer's disease (AD) is a feasible target for intervention in individuals at risk for this disease. This single-site (Baltimore, Maryland) phase II clinical trial is a 2-week, randomized, placebo-controlled crossover study of the effects of the selective glucocorticoid receptor antagonist, CORT108297, on cognitive test performance in 26 individuals with mild cognitive impairment (MCI) due to AD and in 26 cognitively normal individuals with an increased risk for AD due to family history, genetics, and/or subjective memory complaints. All subjects will participate in a brief stressor (public speaking and mental arithmetic) and provide saliva samples so investigators can measure stress hormone response. Then, following 2 weeks of treatment with placebo or CORT108297, in counterbalanced order, participants will complete cognitive tests assessing memory and executive function. All study participants will receive CORT108297 and placebo over the course of this 10-week trial that requires 6 in-person study visits. The primary aims will compare the effects of CORT108297 to placebo on cognitive test performance in individuals with MCI due to AD and in individuals at risk for AD, and describe the side effects of CORT108297 in study participants. Secondary aims will identify subject characteristics that predict positive response to study drug.

Sponsor: Johns Hopkins University

Who Can Participate

Inclusion Criteria

for all subjects:
At least 55 years of age;
Body mass index \>17 and \<30;
Post-menopausal (if female)
Non-smoker;
Availability of a study partner who has frequent contact with the subject (10+ hours/week in person and by telephone), and is able to provide an independent evaluation of functioning;
Native English speaker;
Good general health with no disease expected to interfere with the study;
Willing and able to participate for the duration of the study.

Exclusion Criteria

for all subjects:
Participation in a therapeutic clinical trial at any time during the study;
Abnormal corrected QT interval using Bazett's formula (QTcB; defined as \> 450 ms for men and \> 470 ms for women) as determined on ECG;
Any significant neurologic disease other than suspected incipient Alzheimer's disease, such as Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma followed by persistent neurologic deficits or known structural brain abnormalities, including lacunes in critical memory structures including the hippocampus and parahippocampal cortex;
Major depression, bipolar disorder within the past 1 year;
History of alcohol or drug dependence;
Any significant systemic illness or unstable medical condition, which could lead to difficulty complying with the protocol;
General surgery within the last 3 months;
Sensory impairment (poor vision or hearing) significant enough to interfere with ability to provide valid cognitive test data;
Treatment within the last six months with antidepressants, neuroleptics, sedative hypnotics, or glucocorticoids;
Treatment within the last six months with medications metabolized by the CYP2C9 or CYP2C19 enzymes, most notably clopidogrel and proton pump inhibitors;
Concurrent use of a CYP3A inhibitor, including grapefruit juice, and St. John's Wort;
Exceptions to these guidelines may be considered on a case-by-case basis at the discretion of the PI.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Baltimore?

Yes, this clinical trial (NCT04601038) has an active research site in Baltimore, MD that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Mild Cognitive Impairment Treatment Options in Baltimore, MD

If you're searching for mild cognitive impairment treatment options in Baltimore, MD, this clinical trial (NCT04601038) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Baltimore research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced mild cognitive impairment specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all mild cognitive impairment clinical trials near you to find additional studies recruiting in your area.

More Heart Attack Trials in Baltimore, MD

See all heart attack clinical trials recruiting in Baltimore — not just this study.

Browse Heart Attack Trials in Baltimore →

Browse More Trials by Condition

Heart Attack TrialsMyocardial Infarction TrialsInterstitial Lung Disease TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Baltimore?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Baltimore, MD